Key result
MASLD was associated with a 35% increased odds of incident chronic kidney disease over 5 years compared to individuals without MASLD.
Why the study?
The updated MASLD framework emphasizes the systemic impact of hepatic steatosis, including kidney dysfunction, motivating evaluation using region-specific FLI cutoffs and updated definitions.
Does higher Fatty Liver Index (FLI) or the presence of MASLD predict reduced eGFR and increased risk of incident CKD in adults?
Cohort (n=9,911)
No
Does higher Fatty Liver Index (FLI) or the presence of MASLD predict reduced eGFR and increased risk of incident CKD in adults?
Odds Ratio: 1.35 (95% CI 1.01–1.79)
p-value: p=0.040
Higher Fatty Liver Index and MASLD are independently associated with impaired kidney function and increased 5-year risk of incident CKD, highlighting the systemic cardiometabolic impact of hepatic steatosis.
May warrant closer renal surveillance in MASLD; hypothesis-generating for shared pathways, needing interventional trials.
BACKGROUND: The updated metabolic dysfunction-associated steatotic liver disease (MASLD) framework highlights the systemic impact of hepatic steatosis, including kidney dysfunction. We investigated both cross-sectional and 5-year longitudinal associations between Fatty Liver Index (FLI) and estimated glomerular filtration rate (eGFR), and between MASLD and Chronic kidney disease (CKD), using region-specific FLI cutoffs and the latest definitions and robust methodology. METHODS: We analyzed 9,911 adults from the Fasa Adults Cohort Study (FACS), including 2,906 with 5-year follow-up. FLI was calculated using sex-specific regionally validated cutoffs. eGFR was estimated using the 2021 CKD-EPI equation. Regression models assessed continuous FLI-eGFR and binary MASLD-CKD associations, with scatter plots to visualize patterns. Models were adjusted for extensive confounders. Subgroup analyses were stratified by sex, obesity, and physical activity, with formal interaction testing. Sensitivity analyses applied the commonly used European FLI ≥ 60 threshold. RESULTS: lower eGFR (p < 0.001). A U-shaped FLI-eGFR association was detected, most prominent in men. Longitudinally, higher FLI predicted greater eGFR decline (β = -1.92; p = 0.005) and MASLD increased CKD risk (OR = 1.41; 95% CI 1.07-1.86), especially among males (OR = 2.27), non-obese (OR = 1.47) and physically active individuals (OR = 1.64). Subgroup differences by obesity and physical activity were descriptive only, as interaction terms were not significant (p > 0.05). Using FLI ≥ 60, cross-sectional results remained significant, whereas longitudinal associations attenuated, suggesting potential misclassification when non-population-specific cutoffs are applied. CONCLUSIONS: Higher FLI and MASLD were associated with impaired kidney function cross-sectionally and prospectively. Region-specific FLI cutoffs resulted in more stable longitudinal associations than the European FLI ≥ 60 threshold, underscoring the relevance of population-calibrated indices. Although sex differences were evident, obesity- and activity-related variations were not statistically confirmed. FLI may offer a practical, scalable tool for early identification of CKD risk. Further studies should validate these findings across diverse populations and assess whether interventions targeting MASLD can mitigate kidney function decline.
No takes yet. Share an insight, caveat, or question.
Bazmi et al. (2025) conducted a cohort in Metabolic dysfunction-associated steatotic liver disease (MASLD) and Chronic Kidney Disease (CKD) (n=9,911). Metabolic dysfunction-associated steatotic liver disease (MASLD) vs. Absence of MASLD was evaluated on Incident Chronic Kidney Disease (CKD) at 5 years (OR 1.35, 95% CI 1.01-1.79, p=0.040). MASLD was associated with a 35% increased odds of incident chronic kidney disease over 5 years compared to individuals without MASLD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: